ST Pharm Co.Ltd (237690) - Net Assets

Latest as of December 2025: ₩593.00 Billion KRW ≈ $401.87 Million USD

Based on the latest financial reports, ST Pharm Co.Ltd (237690) has net assets worth ₩593.00 Billion KRW (≈ $401.87 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩782.57 Billion ≈ $530.33 Million USD) and total liabilities (₩189.56 Billion ≈ $128.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of ST Pharm Co.Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩593.00 Billion
% of Total Assets	75.78%
Annual Growth Rate	16.63%
5-Year Change	83.61%
10-Year Change	89.31%
Growth Volatility	42.87

ST Pharm Co.Ltd - Net Assets Trend (2015–2025)

This chart illustrates how ST Pharm Co.Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is ST Pharm Co.Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for ST Pharm Co.Ltd (2015–2025)

The table below shows the annual net assets of ST Pharm Co.Ltd from 2015 to 2025. For live valuation and market cap data, see ST Pharm Co.Ltd stock valuation.

Year	Net Assets	Change
2025-12-31	₩593.00 Billion ≈ $401.87 Million	+17.90%
2024-12-31	₩502.99 Billion ≈ $340.87 Million	+30.00%
2023-12-31	₩386.91 Billion ≈ $262.20 Million	+14.59%
2022-12-31	₩337.63 Billion ≈ $228.81 Million	+4.54%
2021-12-31	₩322.97 Billion ≈ $218.87 Million	+9.36%
2020-12-31	₩295.33 Billion ≈ $200.14 Million	-1.87%
2019-12-31	₩300.96 Billion ≈ $203.95 Million	-9.23%
2018-12-31	₩331.57 Billion ≈ $224.70 Million	-5.56%
2017-12-31	₩351.08 Billion ≈ $237.92 Million	+12.08%
2016-12-31	₩313.24 Billion ≈ $212.28 Million	+146.01%
2015-12-31	₩127.33 Billion ≈ $86.29 Million	--

Equity Component Analysis

This analysis shows how different components contribute to ST Pharm Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 168.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩204.24 Billion	34.42%
Other Components	₩389.20 Billion	65.58%
Total Equity	₩593.44 Billion	100.00%

ST Pharm Co.Ltd Competitors by Market Cap

The table below lists competitors of ST Pharm Co.Ltd ranked by their market capitalization.

Company	Market Cap
Poya International Co Ltd TWO:5904	$1.93 Billion
Stolt-Nielsen Limited LSE:0OHK	$1.93 Billion
Cal-Comp Electronics (Thailand) Public Company Limited TW:9105	$1.93 Billion
Qingdao NovelBeam Technology Co. Ltd. A SHG:688677	$1.93 Billion
Suzhou Nanomicro Technology Co Ltd SHG:688690	$1.93 Billion
Super Retail Group Ltd AU:SUL	$1.93 Billion
CETC Digital Technology Co Ltd SHG:600850	$1.92 Billion
Zhejiang Huatie Constr Safety SHG:603300	$1.92 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ST Pharm Co.Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 503,132,372,460 to 593,442,577,190, a change of 90,310,204,730 (17.9%).
Net income of 54,991,748,140 contributed positively to equity growth.
Dividend payments of 10,076,444,000 reduced retained earnings.
Other factors increased equity by 45,394,900,590.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩54.99 Billion	+9.27%
Dividends Paid	₩10.08 Billion	-1.7%
Other Changes	₩45.39 Billion	+7.65%
Total Change	₩-	17.95%

Book Value vs Market Value Analysis

This analysis compares ST Pharm Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.32x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 9.00x to 5.32x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩16946.43	₩152500.00	x
2017-12-31	₩18818.76	₩152500.00	x
2018-12-31	₩17772.78	₩152500.00	x
2019-12-31	₩16131.97	₩152500.00	x
2020-12-31	₩15830.19	₩152500.00	x
2021-12-31	₩17171.46	₩152500.00	x
2022-12-31	₩17950.76	₩152500.00	x
2023-12-31	₩20445.26	₩152500.00	x
2024-12-31	₩24965.77	₩152500.00	x
2025-12-31	₩28672.48	₩152500.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently ST Pharm Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.27%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 16.58%
• Asset Turnover: 0.42x
• Equity Multiplier: 1.32x
Recent ROE (9.27%) is above the historical average (6.34%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	22.72%	18.25%	0.59x	2.10x	₩14.10 Billion
2016	19.61%	30.66%	0.54x	1.17x	₩30.10 Billion
2017	12.82%	22.19%	0.53x	1.09x	₩9.89 Billion
2018	-2.80%	-9.48%	0.28x	1.04x	₩-42.42 Billion
2019	-6.16%	-19.87%	0.27x	1.13x	₩-48.62 Billion
2020	-4.11%	-9.79%	0.28x	1.51x	₩-41.68 Billion
2021	1.03%	2.00%	0.33x	1.54x	₩-28.99 Billion
2022	5.33%	7.22%	0.44x	1.69x	₩-15.76 Billion
2023	5.09%	6.87%	0.42x	1.76x	₩-18.87 Billion
2024	6.90%	12.68%	0.38x	1.43x	₩-15.60 Billion
2025	9.27%	16.58%	0.42x	1.32x	₩-4.35 Billion

Industry Comparison

This section compares ST Pharm Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $100,225,866,645
Average return on equity (ROE) among peers: 0.62%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
ST Pharm Co.Ltd (237690)	₩593.00 Billion	22.72%	0.32x	$1.93 Billion
Sam Chun Dang Pharm. Co. Ltd (000250)	$298.46 Billion	-3.48%	0.37x	$6.03 Billion
DongKoo Bio&Pharma Co. Ltd (006620)	$105.33 Billion	1.93%	1.32x	$33.52 Million
NatureCell Co.Ltd (007390)	$39.48 Billion	-1.17%	0.30x	$688.81 Million
Sam-A Pharm. Co. Ltd (009300)	$110.58 Billion	8.88%	0.25x	$68.66 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$169.03 Billion	11.15%	0.19x	$89.89 Million
WooGene B&G Co. Ltd (018620)	$29.85 Billion	-6.92%	1.60x	$13.13 Million
Oscotec Inc (039200)	$26.33 Billion	-13.85%	0.55x	$990.30 Million
EstechPharma Co. Ltd (041910)	$111.39 Billion	9.84%	0.11x	$59.21 Million
Komipharm International Co. Ltd (041960)	$76.28 Billion	-3.69%	0.60x	$380.81 Million
Eagle Veterinary Technology Co.Ltd (044960)	$35.53 Billion	3.47%	0.29x	$34.35 Million

About ST Pharm Co.Ltd

KQ:237690 Korea Pharmaceuticals

Market Cap

$1.93 Billion

₩2.85 Trillion KRW

Market Cap Rank

#6414 Global

#168 in Korea

Share Price

₩152500.00

Change (1 day)

-6.67%

52-Week Range

₩71600.00 - ₩168700.00

All Time High

₩168700.00